Welcome to eviQ
A free resource of evidence-based, consensus driven cancer treatment protocols and information for use at the point of care. eviQ is developed for the Australian context and supports health professionals in the delivery of cancer treatments.
This new course developed by The Human Genetics Society of Australia (HGSA) and the Clinical Oncology Society of Australia (COSA) Cancer Special Interest Group (SIG) provides a step-by-step approach to the mainstreaming process and its role in the management of cancer patients. It also outlines how oncology teams can implement mainstream genetic testing in their oncology units.
Complete the survey to help us understand the impact of the ADDIKD guideline and the implementation of its recommendations into eviQ protocols on clinician practice and cancer centres. You could win a $50 gift voucher too!
Uridine triacetate, an antidote for fluoropyrimidine overdose or overexposure, now has a confirmed supply pathway in Australia through The Peter MacCallum Centre in Melbourne, Victoria.
We've developed this short animation 'eviQ - A safe place to start' to help explain eviQ's place in the clinical landscape and its intention of use.
Title